M. Ruiz Borrego-rekin lankidetzan egindako argitalpenak (3)

2023

  1. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

2020

  1. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2017

  1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700